Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

by @JTC_PALIdev | Jul 11, 2024 | Press Releases

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track...

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

by @JTC_PALIdev | Jun 24, 2024 | Press Releases

Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for...

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

by @JTC_PALIdev | Jun 21, 2024 | Press Releases

– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative...

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

by @JTC_PALIdev | Jun 11, 2024 | Press Releases

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 — Palisade Bio,...

Palisade Bio to Present at the Virtual Investor Pitch Conference

by @JTC_PALIdev | Jun 10, 2024 | Press Releases

Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for...

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

by @JTC_PALIdev | May 21, 2024 | Press Releases

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a...